New Insights on Elective Single Embryo Transfer from Nationwide IVF Patient Survey to be presented at the American Society for Reproductive Medicine

Share Article

Progyny, the leading company dedicated to helping ensure patients control their fertility journey and achieve the best possible outcomes, announced today new insights on factors associated with increased likelihood of acceptance of elective single embryo transfer (eSET) for patients undergoing IVF from a nationwide IVF patient survey will be presented at the American Society for Reproductive Medicine (ASRM) in Baltimore, MD.

News Image

Progyny, the leading company dedicated to helping ensure patients control their fertility journey and achieve the best possible outcomes, announced today new insights on factors associated with increased likelihood of acceptance of elective single embryo transfer (eSET) for patients undergoing IVF from a nationwide IVF patient survey will be presented at the American Society for Reproductive Medicine (ASRM) in Baltimore, MD.

“Findings from this analysis provide some actionable recommendations on how we, as a community, can be doing more to help educate patients regarding the number of embryos to transfer,” stated Barbara Collura, President and CEO of RESOLVE: The National Infertility Association.  “Patients undergoing IVF want to become parents, and are faced with many decisions during their family building journey.  We can all do better to educate and inform those considering IVF on the risks of a multiple birth and what options are available to them.  And we know that lack of insurance coverage for this medical procedure can affect their decision making.”

The studies show that targeted education regarding risks of multiple gestation and benefits of eSET through multiple channels, earlier discussions on transfer order, and emphasizing the potential health risks to offspring are key areas of opportunity to influence a patient’s acceptance of single embryo transfer (SET).   In addition the study evaluated demographics and found patients living in the Midwest may be least likely to have eSET and may benefit most from increased education. 

Despite the data that demonstrates multiple pregnancy rates are associated with more adverse health outcomes to infants along with increased risk of pregnancy and birth complications(1), the practice of eSET is still underutilized.  Women who are electing single embryo transfer represent less than 9% of all IVF cycles.(2)  In addition there is also significant economic burden, recent published data has shown the healthcare costs (up to one year post birth) of twins to be 4 times, and triplets 18 times, more than the costs of a singleton birth.

“Our company puts the patient at the center of everything we do,” said Gina Bartasi, Chief Executive Officer, “therefore, we embrace these opportunities to better understand the patient perspective so that we can help provide relevant and meaningful programs to support patients undergoing IVF.”

The results are based on a nationwide IVF patient survey that was conducted by RESOLVE: The National Infertility Association and sponsored by Progyny.  Five abstract presentations will be presented by University of Iowa Hospitals who completed all the analysis. 

Full session details and data presentation listings for the 2015 meeting can be found on the ASRM website at http://www.asrmannualmeeting.org.

1-Practice Committee of American Society for Reproductive Medicine. Fertility and Sterility. April 2012.
2-SART.org (Society for Assisted Reproductive Technology, National Summary Report)

About Progyny: 
Progyny, the combined entity of Auxogyn, Inc. and Fertility Authority LLC, is the first company to provide fertility patients with easy accessibility to high quality doctors, price transparency, and financing, coupled with extraordinary clinical expertise and proprietary clinical solutions. Rooted in clinical excellence and serving as a champion for the consumer, the company is committed to helping ensure that patients control their fertility journey and achieve the best possible outcome. Progyny is privately held and its investors include Kleiner Perkins Caufield & Byers, TPG Biotech, SR One and Merck Serono Ventures. The company is headquartered in New York, NY, with operations in Menlo Park, CA. For more information, please visit http://www.progyny.com.

About RESOLVE: The National Infertility Association: 
Established in 1974, RESOLVE: The National Infertility Association is a non-profit organization with the only established, nationwide network mandated to promote reproductive health and to ensure equal access to all family building options for men and women experiencing infertility or other reproductive disorders. One in eight U.S. couples of childbearing age has trouble conceiving or carrying a pregnancy to term.  RESOLVE addresses this public health issue by providing community to these women and men, connecting them with others who can help, empowering them to find resolution and giving voice to their demands for access to all family building options.  For more information, visit http://www.RESOLVE.org.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Robin McCarthy
Progyny
646-350-0748
Email >
Follow us on
Visit website